TR-1: Standard form for notification of major holdings
LONDON, 25 June 2020 - Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) (LSE: HIK) announces as follows:
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
|
|
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: |
Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) |
||||||
|
Non-UK issuer |
|
|||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an "X") |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
|
|||||
|
An event changing the breakdown of voting rights |
|
|||||
|
Other (please specify)iii: |
|
|||||
|
3. Details of person subject to the notification obligationiv |
||||||
|
Name |
Boehringer Ingelheim Invest GmbH |
|||||
|
City and country of registered office (if applicable) |
Ingelheim am Rhein, Germany |
|||||
|
4. Full name of shareholder(s) (if different from 3.)v |
||||||
|
Name |
N/A |
|||||
|
City and country of registered office (if applicable) |
N/A |
|||||
|
5. Date on which the threshold was crossed or reachedvi: |
23 June 2020 25 June 2020 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
25 June 2020 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuervii |
||
|
Resulting situation on the date on which threshold was crossed or reached |
23 June 2020: 12,833,233 shares bought back by the issuer with a resultant position of 11.16%. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0%. |
0 |
23 June 2020: 12,833,233 shares bought back by the issuer with a resultant position of 11.16%. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0%. |
23 June 2020: 12,833,233 shares bought back by the issuer with a resultant position of 27,166,767. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0. |
||
|
Position of previous notification (if applicable) |
16.67% |
0 |
16.67% |
|
||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
|||||||||
|
A: Voting rights attached to shares |
|||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rightsix |
% of voting rights |
|||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
|
Ordinary shares of 10 pence each (GB00B0LCW083) |
23 June 2020: 12,833,233 shares bought back by the issuer with a resultant position of 27,166,767. 25 June 2020: Remaining 27,166,767shares sold in a placing with a resultant position of 0. |
0 |
23 June 2020: 12,833,233 shares bought back by the issuer with a resultant position of 11.16%. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0%. |
0 |
|||||
|
SUBTOTAL 8. A |
23 June 2020: 27,166,767 25 June 2020: 0 |
23 June 2020: 11.16% 25 June 2020: 0% |
|||||||
|
|
|||||||||
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|||||
|
N/A |
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
SUBTOTAL 8. B 1 |
|
|
|||||
|
|
|||||||||
|
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlementxii |
Number of voting rights |
% of voting rights |
||||
|
N/A |
|
|
|
|
|
||||
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
||||
|
|
|
|
SUBTOTAL 8.B.2 |
|
|
||||
|
|
|||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
|
|||
|
Full chain of controlled undertakings through which the voting rights and/or the |
X |
|||
|
Namexv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
C.H. Boehringer Sohn AG & Co. KG |
0 |
0 |
0 |
|
|
Boehringer Ingelheim Corporate Center GmbH |
0 |
0 |
0 |
|
|
Boehringer Ingelheim Verwaltungs GmbH |
0 |
0 |
0 |
|
|
Boehringer Ingelheim International GmbH |
0 |
0 |
0 |
|
|
Boehringer Ingelheim Auslandsbeteiligungs GmbH |
0 |
0 |
0 |
|
|
|
||||
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
N/A |
|||
|
The number and % of voting rights held |
N/A |
|||
|
The date until which the voting rights will be held |
N/A |
|||
|
|
||||
|
11. Additional informationxvi |
||||
|
None |
||||
|
Place of completion |
Germany |
|
Date of completion |
Buyback by the issuer completed 23 June 2020. Sale in the placing completed 25 June 2020. |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
